Page last updated: 2024-10-22

alosetron and Adverse Drug Event

alosetron has been researched along with Adverse Drug Event in 3 studies

alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.

Research Excerpts

ExcerptRelevanceReference
" Gastroenterologists and their patients have been affected adversely by removal from the marketplace of two licensed agents for irritable bowel syndrome (IBS): alosetron and tegaserod."3.74Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. ( Johnson, DA; Schiller, LR, 2008)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, Z1
Shi, Q1
Ding, D1
Kelly, R1
Fang, H1
Tong, W1
Smith, DA1
Schmid, EF1
Schiller, LR1
Johnson, DA1

Reviews

1 review available for alosetron and Adverse Drug Event

ArticleYear
Drug withdrawals and the lessons within.
    Current opinion in drug discovery & development, 2006, Volume: 9, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbolines; Colitis, Ischemic; Drug Design; Drug-R

2006

Other Studies

2 other studies available for alosetron and Adverse Drug Event

ArticleYear
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
    PLoS computational biology, 2011, Volume: 7, Issue:12

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da

2011
Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
    The American journal of gastroenterology, 2008, Volume: 103, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Clinical Trials as Topic; Drug Approval; Drug L

2008